

Neosoma Incorporates Wholly-Owned Swiss Subsidiary
Expands European Collaborations and Advances Brain Tumor Solutions

Groton, Massachusetts and Bern, Switzerland, January 15, 2025 - [Neosoma, Inc.](#), developer of a software medical device platform to help advance brain cancer care and clinical trials, announced today the incorporation of a wholly-owned subsidiary in Bern, Switzerland: Neosoma GmbH.

Neosoma's mission is to advance brain tumor clinical care and clinical trials through a portfolio of AI-based software technologies that provide clinicians and researchers with greater insights to help guide treatment techniques and clinical decisions.

In 2019, Neosoma established a close research and development collaboration with the University of Bern (UBern), centered around a long-term licensing agreement leveraging deep learning technology developed at UBern's ARTORG Center for Biomedical Engineering Research (ARTORG).

Since then, the Neosoma - UBern collaboration has grown, and Neosoma has established itself as the leading provider of tumor mapping and volumetric measurement software in the neuro-oncology space.

"Incorporating a subsidiary in Bern allows Neosoma to deepen its research collaboration with the amazing teams at UBern and Inselspital, expand its development footprint through targeted AI development hires, and serve as a base for European commercialization. We are thrilled to expand our partnership with our close colleagues in Bern," said Ken Kolodziej, Neosoma's CEO.

"Our research laboratory, along with many others worldwide, has been deeply committed to advancing AI-based brain tumor segmentation. Achieving the translation of our findings and expertise into a solution now accessible to clinics marks a significant milestone in our journey. We are thrilled about the future and the exciting next steps for Neosoma GmbH as we continue to drive innovation in this critical area" said Mauricio Reyes, scientific leader at ARTORG, Univ. Bern.

Mr. Kolodziej and Prof. Dr. Mauricio Reyes, Group Head of ARTORG's Medical Image Analysis Group, will serve as Directors of Neosoma GmbH.

About Neosoma

Neosoma is focused on advancing the treatment of brain cancers through an integrated portfolio of innovative, artificial intelligence-based software products combined with a Clinical Management Software Platform. Neosoma's comprehensive SaaS solution is a first-of-its-kind technology in the neuro-oncology space, helping physicians to make better treatment decisions to improve clinical outcomes.

Starting with its initial software based medical device, Neosoma Glioma, the company is developing a full suite of software technologies to become the global leader in the neuro-oncology software field.

About the ARTORG Center of the University of Bern

The ARTORG Center at the University of Bern integrates biomedical engineering and medicine to develop innovative healthcare solutions. As Europe's only engineering department within a medical faculty, ARTORG focuses on translational research in areas such as AI, robotics, biomechanics, and surgical technologies. Through close clinical collaboration and strong industry ties, the center drives the discovery, development, and translation of biomedical innovations to enhance patient care.

Media Contact

For additional information or inquiries, please contact:

John Liedtky

Chief Strategy and Commercialization Officer, Neosoma Inc.

john.liedtky@neosomainc.com

760-822-1991